Peer-reviewedCC BY-NC-ND 4.0Scientific Reports
Apigenin suppresses ovarian cancer cell growth by disrupting TGF-beta1-mediated cancer–stroma interaction via AKT inhibition
Related
- The EMA Qualification Opinion for CYP Inhibition‐Mediated Drug–Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15
- Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway [Retraction].
- Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling
- Metformin promotes apoptosis of senescent chondrocytes by disrupting the Bcl-xL/Mcl-1–Bak interaction
- PARG inhibition suppresses osteoclast differentiation through transcriptional activation of an NRF2-dependent pathway
BibTeX
@article{kwon2026apigenin,
title = {{Apigenin suppresses ovarian cancer cell growth by disrupting TGF-beta1-mediated cancer–stroma interaction via AKT inhibition}},
author = {Youngjoo Kwon and Somin Lee and Hyunjin Seo and Soo-Jung Lee},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-77491-9},
url = {https://www.nature.com/articles/s41598-026-77491-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Apigenin suppresses ovarian cancer cell growth by disrupting TGF-beta1-mediated cancer–stroma interaction via AKT inhibition
AU - Youngjoo Kwon
AU - Somin Lee
AU - Hyunjin Seo
AU - Soo-Jung Lee
PY - 2026
DA - 2026/10/28
JO - Scientific Reports
DO - 10.1038/s41598-026-77491-9
UR - https://www.nature.com/articles/s41598-026-77491-9
SN - 2045-2322
ER -